Latest News

Dupilumab for Atopic Dermatitis: 7 Years Later
Dupilumab for Atopic Dermatitis: 7 Years Later

March 28th 2024

Today officially marks 7 years since the US FDA approved dupilumab for the treatment of atopic dermatitis. Here's a look back at its approval timeline and all it has accomplished in the dermatology world in the time since.

Amlitelimab Demonstrates Sustained Improvements in Atopic Dermatitis Signs and Symptoms
Amlitelimab Demonstrates Sustained Improvements in Atopic Dermatitis Signs and Symptoms

March 21st 2024

Connecting COVID-19 Research to Impact on Patients With Atopic Dermatitis
Connecting COVID-19 Research to Impact on Patients With Atopic Dermatitis

March 18th 2024

Red, Itchy, And AD Until Proven Otherwise
Red, Itchy, And AD Until Proven Otherwise

March 12th 2024

Discussing Late-Breaking INTEGUMENT-PED Data With Arcutis' Chief Medical Officer, Patrick Burnett, MD, PhD, FAAD
Discussing Late-Breaking INTEGUMENT-PED Data With Arcutis' Chief Medical Officer, Patrick Burnett, MD, PhD, FAAD

March 10th 2024

Video Series
Video Interviews
Podcasts

More News

© 2024 MJH Life Sciences

All rights reserved.